Overview

Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA)

Status:
Terminated
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the serum concentration of tabalumab after the administration using either prefilled syringe or auto-injector after the initial loading dose and after 12 weeks of treatment. Treatment period is followed by 40 weeks optional safety extension.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Antibodies, Monoclonal